Glaukos Corporation

NYSE:GKOS Stok Raporu

Piyasa değeri: US$7.8b

Glaukos Yönetim

Yönetim kriter kontrolleri 3/4

Glaukos CEO'su Tom Burns, Apr2002 tarihinde atandı, in görev süresi 22.58 yıldır. in toplam yıllık tazminatı $ 8.65M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.8% maaş ve 91.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.68% ine doğrudan sahiptir ve bu hisseler $ 208.73M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.1 yıl ve 10.3 yıldır.

Anahtar bilgiler

Tom Burns

İcra Kurulu Başkanı

US$8.7m

Toplam tazminat

CEO maaş yüzdesi8.8%
CEO görev süresi22.6yrs
CEO sahipliği2.7%
Yönetim ortalama görev süresi4.1yrs
Yönetim Kurulu ortalama görev süresi10.3yrs

Son yönetim güncellemeleri

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

May 24
Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?

Sep 18
Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?

Glaukos Corporation: Ripe For Some Consolidation

Sep 11

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 28
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price

Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Aug 07
Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear

Jul 18
Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear

Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt

Jun 11
Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt

Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun

May 30

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

May 24
Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Apr 22
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Apr 04
Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Feb 21
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Is Glaukos (NYSE:GKOS) A Risky Investment?

Jan 21
Is Glaukos (NYSE:GKOS) A Risky Investment?

Glaukos: Remains A Hold Due To High Valuation And Negative Profitability

Jan 09

Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Dec 20
Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Nov 03
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Oct 05
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support

Sep 01

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Glaukos: Revising To Buy On These 3 Catalytic Factors

Jun 16

Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Apr 19
Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Feb 19
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

Feb 14

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Oct 16
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80

Aug 24

Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision

Aug 04

CEO Tazminat Analizi

Tom Burns'un ücretlendirmesi Glaukos'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$150m

Jun 30 2024n/an/a

-US$159m

Mar 31 2024n/an/a

-US$141m

Dec 31 2023US$9mUS$765k

-US$135m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$126m

Mar 31 2023n/an/a

-US$139m

Dec 31 2022US$6mUS$730k

-US$99m

Sep 30 2022n/an/a

-US$90m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021US$7mUS$702k

-US$50m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$83m

Dec 31 2020US$6mUS$608k

-US$120m

Sep 30 2020n/an/a

-US$73m

Jun 30 2020n/an/a

-US$71m

Mar 31 2020n/an/a

-US$37m

Dec 31 2019US$6mUS$644k

US$15m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018US$5mUS$625k

-US$13m

Sep 30 2018n/an/a

-US$14m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$5mUS$600k

-US$92k

Tazminat ve Piyasa: Tom 'ın toplam tazminatı ($USD 8.65M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 7.94M ).

Tazminat ve Kazançlar: Tom şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Tom Burns (63 yo)

22.6yrs

Görev süresi

US$8,654,684

Tazminat

Mr. Thomas William Burns, also known as Tom, has been the Chief Executive Officer at Glaukos Corporation since April 1, 2022 and serves as its Chairman of the Board since December 31, 2021. He had Presiden...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Thomas Burns
Chairman & CEO22.6yrsUS$8.65m2.68%
$ 208.7m
Joseph Gilliam
President & COO2.6yrsUS$4.18m0.047%
$ 3.6m
Alex Thurman
Senior VP & CFO2.6yrsUS$2.36m0.052%
$ 4.1m
Tomas Navratil
Chief Development Officer4.1yrsUS$2.57m0.048%
$ 3.8m
Mory Gharib
Co-Founderno dataVeri yokVeri yok
Christopher Lewis
Vice President of Investor Relations & Corporate Affairsno dataVeri yokVeri yok
Robert Davis
Senior VPno dataVeri yokVeri yok
Diana Scherer
VP of Compliance & Deputy General Counselno dataVeri yokVeri yok
Michele Allegretto
Senior Vice President of Human Resources9.5yrsVeri yokVeri yok
Chris Calcaterra
Executive Vice President of Global Commercial Operations2.6yrsUS$198.66kVeri yok
L. Katz
Chief Medical Officerno dataVeri yokVeri yok
Jane Rady
Senior Vice President of Corporate Strategy & Business Development6.6yrsVeri yokVeri yok

4.1yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: GKOS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.1 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Thomas Burns
Chairman & CEO22.7yrsUS$8.65m2.68%
$ 208.7m
Gilbert Kliman
Independent Director4.7yrsUS$259.00k0.054%
$ 4.2m
Richard Lindstrom
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Aimee Weisner
Independent Director10.3yrsUS$259.00k0.075%
$ 5.8m
Mark Foley
Lead Independent Director10.3yrsUS$319.38k0.054%
$ 4.2m
David Hoffmeister
Independent Director10.3yrsUS$262.13k0.066%
$ 5.1m
Iqbal Ahmed
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Thomas Samuelson
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Marc Stapley
Independent Director10.3yrsUS$273.39k0.050%
$ 3.9m
Kuldev Singh
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Richard Lewis
Member of Scientific Advisory Boardno dataVeri yokVeri yok
John Berdahl
Member of Scientific Advisory Boardno dataVeri yokVeri yok

10.3yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GKOS 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.3 yıldır).